Newswire (Published: Tuesday, January 2, 2018, Received: Thursday, December 28, 2017, 2:55:20 PM CST)

Word Count: 426

University of Palermo Reports Findings in Prostate Cancer (The Clinical Efficacy of Radium-223 for Bone Metastasis in Patients with Castration-Resistant Prostate Cancer: An Italian Clinical Experience)

By a News Reporter-Staff News Editor at Cancer Weekly -- Investigators discuss new findings in Oncology - Prostate Cancer. According to news originating from Palermo, Italy, by NewsRx correspondents, research stated, "Prostate cancer frequently causes bone metastases and skeletal events that impair quality of life (QoL) and survival. The alpha emitter radium-223 is a new drug that improves treatment in men with castration-resistant prostate cancer (CRPC) and bone metastases."

Our news journalists obtained a quote from the research from the University of Palermo, "Our aim was to evaluate the effectiveness of radium-223. In this retrospective study we enrolled 48 subjects. Pain reduction, alkaline phosphatase (ALP), time to first symptomatic skeletal event, and QoL were the variables we evaluated. Radium-223 was well tolerated, with a manageable toxicity profile and a modest objective response rate. A considerable difference in serum ALP levels before and after treatment was observed, with a significant correlation between pain relief and QoL, which showed a value of R2 to 0.44 with a slope of 1.50 (p=0.0021). Radium-223 showed a clinical benefit, with a reduction in pain symptoms in 58% of patients."

According to the news editors, the research concluded: "Radium-223 was shown to be an effective and well-tolerated therapeutic option in patients with metastatic CRPC progressing after docetaxel plus prednisone treatment."

For more information on this research see: The Clinical Efficacy of Radium-223 for Bone Metastasis in Patients with Castration-Resistant Prostate Cancer: An Italian Clinical Experience. Oncology, 2017;():. (Karger -; Oncology -

The news correspondents report that additional information may be obtained from R. De Luca, Dept. of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy. Additional authors for this research include R.P. Costa, V. Tripoli, A. Murabito and G. Cicero (see also Oncology - Prostate Cancer).

The direct object identifier (DOI) for that additional information is: This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Keywords for this news article include: Italy, Europe, Radium, Palermo, Oncology, Bone Research, Prostate Cancer, Quality of Life, Health and Medicine, Prostatic Neoplasms, Radioactive Elements, Alkaline Earth Metals.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2018, NewsRx LLC


Southern Europe


Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Health Sciences
            Medical Research